This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by van Oortmarssen, G. Articles by Habbema, J. Search for Related Content PubMed PubMed Citation Articles by van Oortmarssen, G. Articles by Habbema, J. Pubmed/NCBI databases Medline Plus Health Information Cancer Social Bookmarking                         What's this?

Modelling issues in cancer screening

Erasmus University, Rotterdam, The Netherlands

Rob Boer

Erasmus University, Rotterdam, The Netherlands

Jdf Habbema

Erasmus University, Rotterdam, The Netherlands

The two main goals of modelling cancer screening are data analysis and evaluation. In data analysis, analytical-numerical statistical models are used to test hypotheses about preclinical disease, the screening test, and the association between early detection and risk of dying from the cancer. Evaluation in cancer screening is supported by model-based prediction of screening effects and cost-effectiveness. Simulation models are suitable for these tasks, and can also be used to identify efficient age-ranges and intervals between screening tests. Striking differences exist between screening models for cervical cancer and breast cancer, which are the two cancer types for which screening is common practice. The two main problems in cervical cancer screening are the proportion of progressive and regressive among screen-detected lesions, and the impact of screening on incidence and mortality. In breast cancer, regression is not (yet) a big issue, and the relationship between screening and mortality reduction has been demonstrated in randomized controlled trials (at least for women older than 50 years). The weakest link in current breast cancer models is the association between earliness of detection and improvement in prognosis. The modelling outcomes and their usefulness are decisively influenced by the data sets that were used in quantifying the model, and the subclassifications of the data that were considered. New or pending modelling issues include HPV-based screening in cervical cancer, screening models for colorectal cancer, the use of surrogate outcome measures and model-based meta-analysis of screening trials.

Statistical Methods in Medical Research, Vol. 4, No. 1, 33-54 (1995)
DOI: 10.1177/096228029500400104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Dewilde and R. Anderson The Cost-Effectiveness of Screening Programs Using Single and Multiple Birth Cohort Simulations: A Comparison Using a Model of Cervical Cancer Med Decis Making, October 1, 2004; 24(5): 486 - 492. [Abstract] [PDF]

				C Sherlaw-Johnson, S Gallivan, D Jenkins, and G. Royston Withdrawing low risk women from cervical screening programmes: mathematical modelling study • Commentary: trials versus models in appraising screening programmes BMJ, February 6, 1999; 318(7180): 356 - 361. [Abstract] [Full Text]

				R. Boer, G. J. van Oortmarssen, and H. J. de Koning Cost-effectiveness of Mammography Screening JAMA, January 10, 1996; 275(2): 111 - 112. [Abstract] [PDF]